The safety and efficacy of VOXZOGO^® (vosoritide) were evaluated in patients with achondroplasia aged 5 to 15 years^1,2

Clinical study overview^1,2

*One patient discontinued due to pain, and one discontinued due to anxiety with injections.

References:

VOXZOGO^® Product Information, 2022
Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020;396:684-692.

This information is intended for healthcare professionals only. Please login/sign up to continue.

You are about to be redirected to the “IQVIA OneKey” healthcare professional authentication portal. By logging in (or signing up) for a OneKey account, you will be provided with access to the BioMarin Australia Healthcare Professional website.

Leaving site

Leaving www.biomarin.com/en-au/

Okay Cancel

You’re about to leave the BioMarin Australia website

The information that you are about to be referred to may not comply with the Australian regulatory requirements or be applicable to Australian users. For particulars specifically relevant to the Australian environment contact BioMarin Pharmaceutical Australia Pty Ltd or refer to the appropriate Product Information document.

Leave this website Close

Study Overview: Clinical Trial

The safety and efficacy of VOXZOGO® (vosoritide) were evaluated in patients with achondroplasia aged 5 to 15 years1,2